Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 2
1968 2
1970 1
1971 1
1975 4
1976 4
1978 3
1979 1
1981 1
1982 2
1983 6
1984 2
1985 1
1986 3
1987 3
1988 4
1989 1
1990 5
1991 1
1993 3
1994 1
1995 5
1996 18
1997 1
1998 3
1999 5
2000 10
2001 14
2002 13
2003 10
2004 8
2005 4
2006 7
2007 7
2008 12
2009 10
2010 13
2011 21
2012 13
2013 11
2014 18
2015 13
2016 16
2017 26
2018 25
2019 18
2020 28
2021 33
2022 34
2023 31
2024 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Results by year

Filters applied: . Clear all
Page 1
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. Among authors: asakawa t. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T. Nakamura Y, et al. Among authors: asakawa t. Nat Med. 2021 Nov;27(11):1899-1903. doi: 10.1038/s41591-021-01553-w. Epub 2021 Nov 11. Nat Med. 2021. PMID: 34764486 Free PMC article. Clinical Trial.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Among authors: asakawa t. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: asakawa t. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N. Okamoto H, et al. Among authors: asakawa t. Br J Cancer. 2007 Jul 16;97(2):162-9. doi: 10.1038/sj.bjc.6603810. Epub 2007 Jun 19. Br J Cancer. 2007. PMID: 17579629 Free PMC article. Clinical Trial.
Pharmacologic Treatment of Restless Legs Syndrome.
Lv Q, Wang X, Asakawa T, Wang XP. Lv Q, et al. Among authors: asakawa t. Curr Neuropharmacol. 2021;19(3):372-382. doi: 10.2174/1570159X19666201230150127. Curr Neuropharmacol. 2021. PMID: 33380302 Free PMC article. Review.
Facing frailty: Are you ready?
Asakawa T, Karako T. Asakawa T, et al. Biosci Trends. 2023 Sep 15;17(4):249-251. doi: 10.5582/bst.2023.01191. Epub 2023 Aug 23. Biosci Trends. 2023. PMID: 37612124 Free article.
Apelin expression is downregulated in T cells in a murine model of chronic colitis.
Yamada D, Kojima Y, Hosoya A, Suzuki M, Watabe T, Inoue T, Tsugawa N, Asakawa T, Yonemoto Y, Onizawa M, Nemoto Y, Oshima S, Shimonaka M, Kuba K, Ishida J, Fukamizu A, Penninger JM, Watanabe M, Okamoto R, Nagaishi T. Yamada D, et al. Among authors: asakawa t. Biochem Biophys Res Commun. 2023 Mar 5;647:72-79. doi: 10.1016/j.bbrc.2023.01.068. Epub 2023 Jan 21. Biochem Biophys Res Commun. 2023. PMID: 36731336
Total Synthesis of (+)-Silybin A.
Inai M, Sagara H, Ueno Y, Ouchi H, Yoshimura F, Asakawa T, Hamashima Y, Kan T. Inai M, et al. Among authors: asakawa t. Chem Pharm Bull (Tokyo). 2024;72(6):570-573. doi: 10.1248/cpb.c24-00276. Chem Pharm Bull (Tokyo). 2024. PMID: 38910121 Free article.
469 results